Serum DR-70 as Biomarker in Breast Cancer

Abstract

DR-70 test measures both Fibrin and Fibrinogen degradation products (FDP) in human serum samples, which created by the organism to limit cancer cells. The aim of the study was to investigate the diagnostic value of serum DR-70 levels in breast cancer and to define the cut-off value of the serum DR-70 with a high diagnostic sensitivity and specificity. This study was conducted as a prospective study in a tertiary-care training and research hospital. One hundred twenty-five patients with benign or malignant breast mass and 33 healthy individuals with no breast lesion on breast imaging methods were included in the study. The patients were divided into three groups: Breast cancer (BC), Benign breast disease (BBD), and Normal controls (NC). Demographical data, breast imaging findings, histopathological data, carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), cancer antigen 15-3 (CA 15-3), and DR-70 levels were evaluated. Diagnostic cut-off value was calculated for serum DR-70 levels by ROC (receiver operating characteristic) analysis. Serum DR-70 levels were significantly higher in BC than other groups (p < 0.001). ROC analysis considered the cut-off value of serum DR-70 0.86 mu g/ml; the sensitivity, specificity, positive predictive value, and negative predictive value were 43.6%, 90.9%, 85%, and 57.7%, respectively. Serum DR-70 level has higher specificity and positive predictive value than other biomarkers for breast cancer. It is thought to be a suitable diagnostic biomarker for breast cancer.